Z-J Zhang1, S Li. 1. Department of Epidemiology and Biostatistics, School of Public Health, Wuhan University, Wuhan, China.
Abstract
AIM: Emerging evidence from epidemiologic studies and basic science suggests a potential antitumour effect of metformin. However, whether metformin improves survival in cancer patients remains inconclusive. METHODS: A literature search was performed using the PubMed, EMbase and SciVerse Scopus databases. Pooled effect estimates were derived using a random-effects meta-analysis model. RESULTS: Of the 28 studies retrieved, the pooled effect estimates showed that metformin was associated with lower risk of all-cause mortality in cancer patients with concurrent diabetes, particularly for breast [pooled relative risk (RR) 0.70, 95% CI 0.55, 0.88; p = 0.003], colorectal (RR 0.70, 95% CI 0.59, 0.84; p < 0.001), ovarian (RR 0.44, 95% CI 0.30, 0.64; p < 0.001) and endometrial cancer (RR 0.49, 95% CI 0.32, 0.73; p = 0.001). In addition, metformin was associated with lower risks of cancer-specific mortality. CONCLUSIONS: The findings of this study support the hypothesis that metformin improves the survival for cancer patients with concurrent diabetes, particularly for breast, colorectal, ovarian, and endometrial cancer. Further investigation is warranted.
AIM: Emerging evidence from epidemiologic studies and basic science suggests a potential antitumour effect of metformin. However, whether metformin improves survival in cancerpatients remains inconclusive. METHODS: A literature search was performed using the PubMed, EMbase and SciVerse Scopus databases. Pooled effect estimates were derived using a random-effects meta-analysis model. RESULTS: Of the 28 studies retrieved, the pooled effect estimates showed that metformin was associated with lower risk of all-cause mortality in cancerpatients with concurrent diabetes, particularly for breast [pooled relative risk (RR) 0.70, 95% CI 0.55, 0.88; p = 0.003], colorectal (RR 0.70, 95% CI 0.59, 0.84; p < 0.001), ovarian (RR 0.44, 95% CI 0.30, 0.64; p < 0.001) and endometrial cancer (RR 0.49, 95% CI 0.32, 0.73; p = 0.001). In addition, metformin was associated with lower risks of cancer-specific mortality. CONCLUSIONS: The findings of this study support the hypothesis that metformin improves the survival for cancerpatients with concurrent diabetes, particularly for breast, colorectal, ovarian, and endometrial cancer. Further investigation is warranted.
Authors: Brandy M Heckman-Stoddard; Andrea DeCensi; Vikrant V Sahasrabuddhe; Leslie G Ford Journal: Diabetologia Date: 2017-08-03 Impact factor: 10.122
Authors: S Amin; G Mhango; J Lin; A Aronson; J Wisnivesky; P Boffetta; Aimee L Lucas Journal: Am J Gastroenterol Date: 2016-07-19 Impact factor: 10.864
Authors: A D Raval; D Thakker; A Vyas; M Salkini; S Madhavan; U Sambamoorthi Journal: Prostate Cancer Prostatic Dis Date: 2015-02-10 Impact factor: 5.554
Authors: Gregory S Calip; Rebecca A Hubbard; Andy Stergachis; Kathleen E Malone; Julie R Gralow; Denise M Boudreau Journal: Pharmacoepidemiol Drug Saf Date: 2014-06-13 Impact factor: 2.890
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254
Authors: Roongruedee Chaiteerakij; Gloria M Petersen; William R Bamlet; Kari G Chaffee; David B Zhen; Patrick A Burch; Emma R Leof; Lewis R Roberts; Ann L Oberg Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544